Severe dyslipidaemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet

Cardiovascular Research

Volumn 87, Issue 4, 2010, Pages 675-682

  Yatera, Yasuko ^a   Shibata, Kiyoko ^a   Furuno, Yumi ^a   Sabanai, Ken ^a   Morisada, Naoya ^a   Nakata, Sei ^a   Morishita, Tsuyoshi ^a   Toyohira, Yumiko ^a   Wang, Ke Yong ^a   Tanimoto, Akihide ^b   Sasaguri, Yasuyuki ^a   Tasaki, Hiromi ^a   Nakashima, Yasuhide ^a   Shimokawa, Hiroaki ^c   Yanagihara, Nobuyuki ^a   Otsuji, Yutaka ^a   Tsutsui, Masato ^a,d  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Atherosclerosis; Nitric oxide; Nitric oxide synthase

Indexed keywords

8 ISOPROSTANE; APOLIPOPROTEIN E; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE SEVERITY; DYSLIPIDEMIA; FOAM CELL; GENE; GENOTYPE; HEART INFARCTION; HISTOPATHOLOGY; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONHUMAN; NPC1L1 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SUDDEN DEATH; SURVIVAL RATE; URINE LEVEL; WILD TYPE;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; DEATH, SUDDEN, CARDIAC; DINOPROST; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GENOTYPE; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; RECEPTORS, LDL; SEVERITY OF ILLNESS INDEX; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TIME FACTORS;

EID: 77955867923     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq092     Document Type: Article

References (32)

1. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-560.
2. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
3. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? Circulation 1997;95:1101-1103.
4. Tsutsui M, Shimokawa H, Otsuji Y, Ueta Y, Sasaguri Y, Yanagihara N. Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. Circ J 2009;73:986-993.
5. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA 2005;102:10616-10621.
6. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, Yanagihara N. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci 2006;102:147-154.
7. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008;117:2211-2223.
8. Tsutsui M, Nakata S, Shimokawa H, Otsuji Y, Yanagihara N. Spontaneous myocardial infarction and nitric oxide synthase. Trends Cardiovasc Med 2008;18:275-279.
9. Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H et al. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002;106: 1729-1735.
10. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002;43:805-814.
11. Morishita T, Tsutsui M, Shimokawa H, Horiuchi M, Tanimoto A, Suda O et al. Vascu-loprotective roles of neuronal nitric oxide synthase. FASEB J 2002;16:1994-1996.
12. Gharavi NM, Baker NA, Mouillesseaux KP, Yeung W, Honda HM, Hsieh X et al. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ Res 2006;98:768-776.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
14. Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006;340:1259-1263.
15. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-353.
16. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-471.
17. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111: 1805-1812.
18. Khedara A, Kawai Y, Kayashita J, Kato N. Feeding rats the nitric oxide synthase inhibitor, L-N(omega)nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr 1996;126:2563-2567.
19. Navarro J, Sanchez A, Saiz J, Ruilope LM, Garcia-Estan J, Romero JC et al. Hormonal, renal, and metabolic alterations during hypertension induced by chronic inhibition of NO in rats. Am J Physiol 1994;267:R1516-R1521.
20. G-nitro-L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 1993;72:387-395.
21. Heim KF, Thomas G, Ramwell PW. Effect of substituted arginine compounds on superoxide production in the rabbit aorta. J Pharmacol Exp Ther 1991;257: 1130-1135.
22. Peterson DA, Peterson DC, Archer S, Weir EK. The nonspecificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 1992;187:797-801.
23. v-nitro-L-arginine benzyl ester, a potent irreversible inhibitor of endothelium dependent relaxation. Biochem Biophys Res Commun 1991;179: 1677-1682.
24. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:1682-1688.
25. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-780.
26. van Haperen R, de Waard M, van Deel E, Mees B, Kutryk M, van Aken T et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 2002;277:48803-48807.
27. Tanaka S, Yashiro A, Nakashima Y, Nanri H, Ikeda M, Kuroiwa A. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 1997;20:361-365.
28. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
29. Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008;205:2053-2063.
30. Libby P. The vascular biology of atherosclerosis. In: Libby P, Bonow R, Mann D, Zipes D, eds. Braunwald's Heart Disease. Philadelphia: Saunders Elsevier; 2008. p985-1002.
31. Nachtigal P, Jamborova G, Pospisilova N, Pospechova K, Solichova D, Zdansky P et al. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis. J Pharm Pharm Sci 2006;9:222-230.
32. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 1993;90:11603-11607.